Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Noveko announces new appointments

This article was originally published in Scrip

Executive Summary

Noveko International has announced two new appointments: Barry McDonald as consultant for projects requiring regulatory approval, and Alain Bolduc as president and general manager of the Noveko Inc subsidiary. Mr McDonald most recently served as interim president and CEO of TS03; before that he was executive director for the US consulting firm The Sage Group. As consultant at Noveko, Mr McDonald will aid the company in its market development efforts across Europe and Asia. Mr Bolduc currently holds the position of chief operating officer of Noveko and will take the role of president and general manager of the subsidiary in lieu of José Larrea. Mr Bolduc will lead the subsidiary in the development and marketing of the company's flagship products based on its patented antimicrobial filtration technology.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC032121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel